Last reviewed · How we verify
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
8 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| TR-701 FA | TR-701 FA | phase 3 | Oxazolidinone antibiotic | Bacterial 70S ribosome | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Arpida AG · 1 shared drug class
- Clinica Universidad de Navarra, Universidad de Navarra · 1 shared drug class
- Fundacion Clinic per a la Recerca Biomédica · 1 shared drug class
- Merck Sharp & Dohme LLC · 1 shared drug class
- Pfizer · 1 shared drug class
- Shenzhen Third People's Hospital · 1 shared drug class
- University of Southern California · 1 shared drug class
- Wuhan Pulmonary Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA):
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline updates — RSS
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline updates — Atom
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/trius-therapeutics-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa. Accessed 2026-05-17.